Health · 1 sources covering this

STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel

FDA advisers are set to consider whether allowing compounding pharmacies to offer largely unproven peptides is a safer bet than the gray-market versions now in use.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel
FDA advisers are set to consider whether allowing compounding pharmacies to offer largely unproven peptides is a safer bet than the gray-market versions now in use.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/543d17b602929554decd0d1c38e225933689a074"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel"></iframe>

STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel

How 1 sources are covering this

STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel

More from Health

Filing of bipartisan Senate bill boosts momentum for office of men’s health

Listen to the Latest ‘KFF Health News Minute’

FDA panel considers easing peptide restrictions

Public Health Improvements Stall Amid Trump’s DEI Crackdown

Reader

Trust & legal

Across the network